Literature DB >> 27639899

The Anticancer Agent, Di-2-Pyridylketone 4,4-Dimethyl-3-Thiosemicarbazone (Dp44mT), Up-Regulates the AMPK-Dependent Energy Homeostasis Pathway in Cancer Cells.

Sukriti Krishan1, Des R Richardson2, Sumit Sahni3.   

Abstract

Adenosine monophosphate-activated protein kinase (AMPK) is a cellular energy sensor that monitors ATP levels. There is also evidence that AMPK has onco-suppressive properties. Iron plays a crucial role in cellular energy transducing pathways and tumor cell proliferation. Therefore, metals (e.g., iron) could play an important role in the regulation of AMPK-dependent pathways. Hence, this investigation examined the effect of the iron and copper chelator and potent anti-cancer agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT), on the AMPK-mediated pathway. These studies demonstrated that Dp44mT, which forms intracellular redox-active complexes with iron and copper, significantly activated AMPK (i.e., p-AMPK/AMPK ratio) in 5 different tumor cell-types. Furthermore, examination of the Dp44mT-metal complexes demonstrated that the effect of Dp44mT on AMPK was due to a dual mechanism: (1) its ability to chelate metal ions; and (2) the generation of reactive oxygen species (ROS). The activation of the AMPK-pathway by Dp44mT was mediated by the upstream kinase, liver kinase B1 (LKB1) that is a known tumor suppressor. Moreover, using AMPKα1-selective silencing, we demonstrated that Dp44mT activated AMPK, resulting in inhibition of acetyl CoA carboxylase 1 (ACC1) and raptor, and activation of Unc-51 like kinase (ULK1). These effects are vital for inhibition of fatty acid synthesis, suppression of protein synthesis and autophagic activation, respectively. Together, this AMPK-mediated repair response aims to rescue the loss of metal ions via chelation and the induction of cytotoxic damage mediated by redox cycling of the Dp44mT-metal ion complex. In conclusion, this study demonstrates for the first time that chelators target the AMPK-dependent pathway.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AMPK; Anticancer Drug; Dp44mT; Energy Homeostasis; Molecular Pharmacology

Mesh:

Substances:

Year:  2016        PMID: 27639899     DOI: 10.1016/j.bbamcr.2016.09.011

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT), an anticancer agent, exerts an anti-inflammatory effect in activated human mast cells.

Authors:  Sun-Young Nam; Na-Ra Han; Kyoung Wan Yoon; Hyung-Min Kim; Hyun-Ja Jeong
Journal:  Inflamm Res       Date:  2017-06-14       Impact factor: 4.575

2.  Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding.

Authors:  Kyung Chan Park; Bekesho Geleta; Lionel Yi Wen Leck; Jasmina Paluncic; Shannon Chiang; Patric J Jansson; Zaklina Kovacevic; Des R Richardson
Journal:  J Biol Chem       Date:  2019-11-19       Impact factor: 5.157

3.  Iron Chelator VLX600 Inhibits Mitochondrial Respiration and Promotes Sensitization of Neuroblastoma Cells in Nutrition-Restricted Conditions.

Authors:  Amanda Westergren Jakobsson; Snehangshu Kundu; Jing Guo; Azazul Chowdhury; Miao Zhao; Emma Lindell; Peter Bergsten; Fredrik J Swartling; Tobias Sjöblom; Xiaonan Zhang
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

4.  Increased intracellular iron in mouse primary hepatocytes in vitro causes activation of the Akt pathway but decreases its response to insulin.

Authors:  Joe Varghese; Jithu James; Sophie Vaulont; Andrew Mckie; Molly Jacob
Journal:  Biochim Biophys Acta Gen Subj       Date:  2018-05-31       Impact factor: 3.770

Review 5.  Lysosomes and Cancer Progression: A Malignant Liaison.

Authors:  Eda R Machado; Ida Annunziata; Diantha van de Vlekkert; Gerard C Grosveld; Alessandra d'Azzo
Journal:  Front Cell Dev Biol       Date:  2021-02-26

Review 6.  The Impact of Iron Chelators on the Biology of Cancer Stem Cells.

Authors:  Julia Szymonik; Kamila Wala; Tomasz Górnicki; Jolanta Saczko; Bartosz Pencakowski; Julita Kulbacka
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

7.  Isoquinoline thiosemicarbazone displays potent anticancer activity with in vivo efficacy against aggressive leukemias.

Authors:  Daniel L Sun; Soumya Poddar; Roy D Pan; Ethan W Rosser; Evan R Abt; Juno Van Valkenburgh; Thuc M Le; Vincent Lok; Selena P Hernandez; Janet Song; Joanna Li; Aneta Turlik; Xiaohong Chen; Chi-An Cheng; Wei Chen; Christine E Mona; Andreea D Stuparu; Laurent Vergnes; Karen Reue; Robert Damoiseaux; Jeffrey I Zink; Johannes Czernin; Timothy R Donahue; Kendall N Houk; Michael E Jung; Caius G Radu
Journal:  RSC Med Chem       Date:  2020-02-24

8.  Synergy of Iron Chelators and Therapeutic Peptide Sequences Delivered via a Magnetic Nanocarrier.

Authors:  Gayani S Abayaweera; Hongwang Wang; Tej B Shrestha; Jing Yu; Kyle Angle; Prem Thapa; Aruni P Malalasekera; Leila Maurmann; Deryl L Troyer; Stefan H Bossmann
Journal:  J Funct Biomater       Date:  2017-06-26

Review 9.  Targeting iron metabolism in cancer therapy.

Authors:  Michael Morales; Xiang Xue
Journal:  Theranostics       Date:  2021-07-25       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.